Page 8 - Patrick Enright News Today : Breaking News, Live Updates & Top Stories | Vimarsana

REUTERS-SCHEDULE/ICYMI:IN CASE YOU MISSED IT–Schedule of Reuters features from this week

By Lauren C. Williams   Sen. Jack Reed (D-R.I.) visiting Army Futures Command in 2020. (U.S. Army photo by Patrick Enright) The must-pass defense policy bill has hit a significant delay in the Senate, because the White House budget is still in progress. Sen. Jack Reed (D-R.I.), chairman for the Senate Armed Services Committee, announced that the committee would delay marking up the 2022 National Defense Authorization Act due to "the uncertainty of the timing of the president's budget submission." "The committee has made a difficult decision to delay the markup of the NDAA until July," Reed...

By Reuters Staff 6 Min Read (Reuters) - Every week, Reuters journalists produce scores of multimedia features and human-interest stories from around the world. FILE PHOTO: Emily Holloway, 24, and Brian Sussman, 23, enjoy a meal together at an indoor table at Canela Bistro and Wine Bar as indoor dining in the Bay Area resumes after being closed for months due to coronavirus disease (COVID-19) restrictions in San Francisco, California, U.S. March 5, 2021. Picture taken March 5, 2021. REUTERS/Brittany Hosea-Small Below are some stories selected by our editors, as well as explanatory context a...

By Lauren C. Williams Mar 03, 2021 The Defense Department will likely have to look even deeper for cost-savings as flat budget looms for 2022 and beyond. Sen. Jack Reed (D-R.I.), the chairman for the Senate Armed Services Committee, said that while topline budget numbers don't adequately reflect value, the Pentagon and military services should look for cost-savings and where reinvestments can be made. "One of the ironies of the Budget Control Act was that it was designed to reduce the deficit but after a while it actually became a force to, I think, increase spending because Republicans wan...

Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease Potential first-in-class disease-modifying biologic in late-stage clinical studies Experienced executive development team from Gilead Sciences News provided by Share this article Share this article SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 /PRNewswire/ -- Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingwo...